[go: up one dir, main page]

EA201400536A1 - METHODS OF PRODUCTION - Google Patents

METHODS OF PRODUCTION

Info

Publication number
EA201400536A1
EA201400536A1 EA201400536A EA201400536A EA201400536A1 EA 201400536 A1 EA201400536 A1 EA 201400536A1 EA 201400536 A EA201400536 A EA 201400536A EA 201400536 A EA201400536 A EA 201400536A EA 201400536 A1 EA201400536 A1 EA 201400536A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
lorcaserin
obesity
overweight
prevention
Prior art date
Application number
EA201400536A
Other languages
Russian (ru)
Other versions
EA022748B1 (en
Inventor
Петр Александрович Белый
Евгений Александрович ЧЕРТОРИЖСКИЙ
Евгений Юрьевич БЕЛОВ
Original Assignee
Делкростон Менеджмент Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Делкростон Менеджмент Лимитед filed Critical Делкростон Менеджмент Лимитед
Priority to EA201400536A priority Critical patent/EA022748B1/en
Priority to PCT/IB2015/001000 priority patent/WO2015185990A1/en
Publication of EA201400536A1 publication Critical patent/EA201400536A1/en
Publication of EA022748B1 publication Critical patent/EA022748B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к медицине, в частности к способам получения двойных солей (1R)-8-хлоро-1-метил-2,3,4,5-тетрагидро-1Н-3-бензазепина (лоркасерина), продуктам способов и композициям для лечения и/или предупреждения ожирения, включающим двойные соли лоркасерина, фталевой кислоты и метформина или лоркасерина, фталевой кислоты и основной аминокислоты. Изобретение относится также к применению указанных фармацевтических композиций для лечения и/или предупреждения нарушений, связанных с избыточным весом и/или ожирением, в том числе и при сахарном диабете, и к способам профилактики или лечения нарушений, связанных с избыточным весом и/или ожирением, в том числе и при сахарном диабете.The invention relates to medicine, in particular to methods for producing double salts of (1R) -8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (lorcaserin), products of methods and compositions for treating and / or preventing obesity, including the double salts of lorcaserin, phthalic acid and metformin or lorcaserin, phthalic acid and the basic amino acid. The invention also relates to the use of these pharmaceutical compositions for the treatment and / or prevention of disorders associated with overweight and / or obesity, including diabetes mellitus, and to methods for the prevention or treatment of disorders associated with overweight and / or obesity, including diabetes.

EA201400536A 2014-06-02 2014-06-02 Methods for producing double salts of lorcaserin (variants), products of said methods, double salts, pharmaceutical compositions for the treatment and/or prophylaxis of obesity-related disorders, the use of same, and method for the treatment and/or prophylaxis of obesity-related disorders EA022748B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EA201400536A EA022748B1 (en) 2014-06-02 2014-06-02 Methods for producing double salts of lorcaserin (variants), products of said methods, double salts, pharmaceutical compositions for the treatment and/or prophylaxis of obesity-related disorders, the use of same, and method for the treatment and/or prophylaxis of obesity-related disorders
PCT/IB2015/001000 WO2015185990A1 (en) 2014-06-02 2015-04-27 Methods for producing double salts of lorcaserin (variants), products of said methods, double salts, pharmaceutical compositions for the treatment and/or prophylaxis of obesity-related disorders, the use of same, and method for the treatment and/or prophylaxis of obesity-related disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201400536A EA022748B1 (en) 2014-06-02 2014-06-02 Methods for producing double salts of lorcaserin (variants), products of said methods, double salts, pharmaceutical compositions for the treatment and/or prophylaxis of obesity-related disorders, the use of same, and method for the treatment and/or prophylaxis of obesity-related disorders

Publications (2)

Publication Number Publication Date
EA201400536A1 true EA201400536A1 (en) 2015-08-31
EA022748B1 EA022748B1 (en) 2016-02-29

Family

ID=53969029

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400536A EA022748B1 (en) 2014-06-02 2014-06-02 Methods for producing double salts of lorcaserin (variants), products of said methods, double salts, pharmaceutical compositions for the treatment and/or prophylaxis of obesity-related disorders, the use of same, and method for the treatment and/or prophylaxis of obesity-related disorders

Country Status (2)

Country Link
EA (1) EA022748B1 (en)
WO (1) WO2015185990A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4782003B2 (en) * 2003-06-17 2011-09-28 アリーナ ファーマシューティカルズ， インコーポレイテッド Benzazepine derivatives useful for the treatment of 5HT2C receptor related diseases
US20090143363A1 (en) * 2007-10-15 2009-06-04 Concert Pharmaceuticals, Inc. Deuterated lorcaserin
US20130315994A1 (en) * 2010-09-01 2013-11-28 Zezhi Jesse Shao Modified-release dosage forms of 5-ht2c agonists useful for weight management
CA2808909A1 (en) * 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids

Also Published As

Publication number Publication date
WO2015185990A1 (en) 2015-12-10
EA022748B1 (en) 2016-02-29

Similar Documents

Publication Publication Date Title
SA519401239B1 (en) Amylin Analogues
MX386595B (en) METHODS FOR THE TREATMENT OF OVERWEIGHT OR OBESITY.
JP2016515522A5 (en)
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
EA201591535A1 (en) SUBSTITUTED DERIVATIVES OF 3-PHENYL-PROPYLAMINE FOR THE TREATMENT OF OPHTHALMOLOGICAL DISEASES AND DISORDERS
PH12017501674A1 (en) Amylin analogues
PH12016501724A1 (en) Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
MX2016013029A (en) Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders.
EA201691789A1 (en) PHARMACEUTICAL COMPOSITIONS AND SALTS OF 1,2,4-OXADIAZOLBENZOIC ACID
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
EA201790442A1 (en) TRICYCLIC NITROGEN-CONTAINING COMPOUNDS FOR THE TREATMENT OF INFECTION CAUSED BY NEISSERIA GONORRHOEAE
EA201890449A1 (en) FUMAGILLINUM HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION AND APPLICATION
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
EA201790223A1 (en) WATER PREPARATION CONTAINING PARACETAMOL AND IBUPROFEN
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
WO2015001541A3 (en) Pharmaceutical film composition
MX2019003725A (en) Metformin glycinate, pharmaceutical compositions comprising the same, and methods of using the same.
MX2018014129A (en) Pharmaceutical composition comprising eteplirsen.
MX2016008968A (en) Organic compounds.
MX2015005733A (en) Tricyclic compounds for use in the treatment and/or control of obesity.
MD4763B1 (en) Pharmaceutical composition
EA201400536A1 (en) METHODS OF PRODUCTION
EA201791398A1 (en) FUMAGILLALLE DERIVATIVES
WO2016044433A3 (en) Metformin derivatives
EA201400308A1 (en) METHOD OF OBTAINING SALT LORKASERIN AND PHTHALIC ACID, PRODUCT OF THE METHOD, PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND / OR PREVENTION SURVEY DISCOUNTS SURVEY OCCURRATED, THEIR APPLICATION AND METHODS HEATSURCHESHURCHES DISCUSSIONS OCCURRATOR

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ RU

PC4A Registration of transfer of a eurasian patent by assignment